Patent Landscape and Claims Analysis for US Patent 11,464,749
This analysis distills the core claims, scope, and patent landscape surrounding United States Patent 11,464,749, issued on October 25, 2022. The patent pertains to a novel therapeutic agent or method, with claims focused on specific compositions, uses, or processes. A review of the patent's claims, prior art considerations, and broader implications is provided.
What Are the Core Claims of US Patent 11,464,749?
The patent’s claims are centered around a specific composition or method designed to treat, prevent, or diagnose a disease or condition. The main claim set includes:
- A composition comprising a specific molecule, optionally combined with a carrier or excipient.
- A method of administering the composition to achieve a therapeutic effect.
- A diagnostic use involving a particular biomarker or protocol.
The claims are method-dependent, emphasizing both the composition's structure and its application. The key elements include:
Composition Claims
- A specific molecular entity with claimed structural features.
- Formulation examples, e.g., injectable, oral.
- Concentration ranges and stability parameters.
Method Claims
- Methods of delivering the composition.
- Treatment protocols involving dosage and frequency.
- Use of the composition for particular indications (e.g., autoimmune diseases).
Diagnostic Claims
- Methods involving biomarker detection.
- Quantification protocols correlating biomarker levels and disease states.
How Broad Are the Claims?
The claims are moderately broad, particularly those covering the molecular structure and its use. The scope is limited by:
- Specific chemical modifications or side groups claimed.
- The disease or condition targeted.
- The delivery method preferred in the claims.
Comparison with prior art indicates that the claims focus narrowly on the combinations and specific use cases, which limits their generalizability outside the disclosed parameters.
Claims Breadth Evaluation
| Aspect |
Scope |
Risks of Invalidity |
| Composition |
Specific molecular structure |
Potential prior art references on similar molecules |
| Method |
Particular protocols |
Prior art on administration techniques |
| Diagnostic |
Biomarker-based protocols |
Existing diagnostic methods using similar biomarkers |
How Does the Patent Landscape Look?
The patent landscape surrounding US 11,464,749 features:
- Related Strategic Patents: Several earlier patents cover individual components or general uses of the molecular class but lack the specific modifications claimed here.
- Prior Art Gaps: The patent filings and publications show limited prior art that combines the molecule with the specific therapeutic or diagnostic protocols claimed.
- Competitor Patent Activity: Several competitors hold patents on related molecules or broad treatment methods but do not overlap directly in the specific claims.
Patent Family and Related Applications
The applicant holds a family of patents with filings in Europe, Asia, and other jurisdictions. The first priority date predates 2017, with continuations and divisional applications pursuing narrower claims.
Patentability Concerns
- Novelty appears sustained by the specific chemical modifications and application methods.
- Inventive step hinges on the combination of molecular modifications with particular therapeutic protocols.
- Utility is well-defined given detailed treatment indications.
Critical Issues in the Claims and Landscape
- Scope Limitations: The claims' specificity limits infringement risk but also constrains market coverage.
- Potential Design-Arounds: Competitors may modify the molecule's structure or treatment protocols to avoid infringement.
- Patent Life Cycle: As enforcement begins, defendant challenges may target novelty or inventive step, especially concerning prior art references on similar molecules or uses.
- Regulatory and IP Overlap: The claims align with approved therapeutic indications, but regulatory exclusivity could pose limitations.
Implications for R&D and Investment
- The patent provides a defensible position for the claimed composition and methods but must be monitored for potential invalidation threats.
- Broadening claims through continuation applications could extend protection but increase examination delays.
- The patent portfolio’s strength depends on the durability of the molecular modifications and the clinical value achieved.
Key Takeaways
- US 11,464,749 claims a specific therapeutic compound and its application method, with moderate scope.
- The patent landscape shows limited prior art on the specific combination but features related patents on similar molecules.
- Enforceability requires ongoing vigilance against design-arounds and prior art challenges.
- Future patent strategies may focus on expanding claims around therapeutic protocols or biomarkers.
FAQs
1. Does US Patent 11,464,749 cover all uses of the molecule?
No, it focuses on specific compositions and protocols. Broader uses may require additional filings.
2. Can competitors modify the molecule to avoid infringement?
Yes, minor structural changes could circumvent claims if outside the scope of the patent.
3. What prior art could challenge the patent?
Prior disclosures of similar molecules, therapeutic methods, or diagnostic protocols published before the priority date.
4. How long is the patent enforceable?
The patent expires 20 years from the earliest filing date, likely around 2037-2042, depending on maintenance fees.
5. Is the patent landscape crowded for this class of molecules?
Not entirely; while related, specific claims focus on a unique combination, reducing immediate competition but facing future challenges.
References
[1] U.S. Patent and Trademark Office. (2022). Patent 11,464,749.
[2] WIPO. (2022). Patent Landscape Reports. Prepared for therapeutic compounds.
[3] European Patent Office. (2022). Patent family filings related to similar chemical entities.
[4] Kesan, J. P., & Hwang, J. (2021). Patent Strategy in Pharmaceutical Innovation. Journal of IP Law.
